Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT00153101
|
| gptkbp:conditionStudied |
gptkb:cardiovascular_disease
high-risk patients intolerant to ACE inhibitors |
| gptkbp:endDate |
2007
|
| gptkbp:fullName |
Trial to Evaluate Cardiovascular Outcomes after Treatment with LCZ696 in Patients with Chronic Heart Failure (PARADIGM-HF)
|
| https://www.w3.org/2000/01/rdf-schema#label |
TRANSCEND trial
|
| gptkbp:location |
international
|
| gptkbp:publicationYear |
2008
|
| gptkbp:publishedIn |
gptkb:The_Lancet
|
| gptkbp:result |
cardiovascular death or hospitalization for heart failure
|
| gptkbp:sponsor |
gptkb:Boehringer_Ingelheim
|
| gptkbp:startYear |
2001
|
| gptkbp:studiedDrug |
gptkb:telmisartan
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|